Visterra Inc, a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains.

Visterra’s novel monoclonal antibody, VIS410, targets a unique, conserved epitope on influenza A, and is being developed as a single administration for the treatment of seasonal and pandemic influenza, according to Zach Shriver, PhD, vice president of research at Visterra.

The company recently initiated a placebo-controlled Phase 2 challenge trial of VIS410 in healthy subjects administered an influenza virus in advance of receiving either VIS410 or placebo. Data from this trial will be available later this year.